Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 3/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11645080 | 0.89 | LMNA (0.46) | PGRTDP1NR3C1LMNAPDE4D | |
| SCHEMBL6707126 | 0.87 | LMNA (0.50) | PGRTDP1NR3C1LMNAPDE4D | |
| SCHEMBL11647496 | 0.83 | CYP17A1 (0.48) | PGRTDP1NR3C1LMNAPDE4D | |
| SCHEMBL11647501 | 0.83 | CYP17A1 (0.48) | PGRTDP1NR3C1LMNAPDE4D | |
| SCHEMBL11645636 | 0.79 | PGR (0.64) | PGRTDP1NR3C1LMNAPDE4D | |
| SCHEMBL14571216 | 0.77 | SHBG (0.68) | PGRNR3C1LMNAARSHBG | |
| SCHEMBL10892429 | 0.77 | SHBG (0.68) | PGRNR3C1LMNAARSHBG | |
| SCHEMBL10892419 | 0.77 | SHBG (0.68) | PGRNR3C1LMNAARSHBG | |
| SCHEMBL10890105 | 0.76 | PGR (0.73) | PGRTDP1NR3C1LMNAPDE4D | |
| SCHEMBL11647042 | 0.76 | PGR (0.73) | PGRTDP1NR3C1LMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4118488-A | 4-Androsten-3-ones and process for the preparation thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | claimed |
| US-7112669-B2 | Processes for preparation of 9,11-epoxy steroids and intermediates useful therein | PHARMACIA CORPORATION (OF PFIZER, INC.) (US) | 2006-09-26 | — | — | US | disclosed |
| US-7038040-B2 | Process for preparation of 9, 11-epoxy steroids and intermediates useful therein | G.D. SEARLE & CO. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050256094-A1 | Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein | G. D. SEARLE & COMPANY (US) | 2005-11-17 | — | — | US | disclosed |
| US-6887991-B1 | Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein | G. D. SEARLE & COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040191874-A1 | Process for preparation of 9, 11-epoxy steroids and intermediates useful therein | G.D. SEARLE & COMPANY | 2004-09-30 | — | — | US | disclosed |
| US-6586591-B2 | Removing an 11 alpha-leaving group from a 20-spiroxane derivative | G.D. SEARLE & CO. | 2003-07-01 | — | — | US | disclosed |
| US-20020042507-A1 | Process for preparation of 9,11-epoxy steroids and intermediates useful therein | NG JOHN S (US) | 2002-04-11 | — | — | US | disclosed |
| EP-1167380-A2 | 11.alpha.-hydroxy-steroid-4,6-dien-3-one compounds and a process for their preparation | G.D. Searle & Co. (US) | 2002-01-02 | — | — | EP | disclosed |
| US-4118488-A | 4-Androsten-3-ones and process for the preparation thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256094-A1 | Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein | CYP4A11, CYP11B1, CYP17A1 | PGR 222/4885TDP1 4355/4885NR3C1 71/4885 |
| US-20020042507-A1 | Process for preparation of 9,11-epoxy steroids and intermediates useful therein | CYP4A11, HSD11B1, DHCR7 | PGR 1061/4885TDP1 4522/4885NR3C1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.